SeraCare Announces Industry's First CNV-Specific Reference Material for Gene Amplifications in Breast, Lung, and Brain Cancer

Date : 02/13/2018 @ 10:08AM
Source : PR Newswire (US)

SeraCare Announces Industry's First CNV-Specific Reference Material for Gene Amplifications in Breast, Lung, and Brain Cancer

MILFORD, Mass., Feb 13, 2018 /PRNewswire/ -- SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, is expanding what is already the most comprehensive suite of clinical genomics development, validation, and QC tools with the launch of the SeraseqTM Breast CNV and Seraseq™ Lung and Brain CNV Mix.  Reference materials that analyze for CNVs allow for a complete and comprehensive variant assessment of DNA-based tumor profiling and diagnostic molecular assays beyond SNVs and indels. These expert-designed products are built with innovative biosynthetic technology that is easily scalable to incorporate new CNVs over time.

SeraCare Life Sciences, Inc.

Copy number variations (CNVs) are DNA segments present at a variable copy number in comparison to a normal genome. Cells that are affected by aberrant copy number changes for certain cancer-associated genes may experience disruption of normal cellular function and, ultimately, tumorigenesis. Next-generation sequencing (NGS) can be used to determine CNVs across multiple genes in a sequencing run.

In order to help clinical labs performing NGS-based tumor profiling for cancer diseases thoroughly understand and characterize their assays, SeraCare has developed the first set of dedicated CNV reference materials for NGS assays - Seraseq Breast CNV Mix and Seraseq Lung and Brain CNV Mix. These unique products were precisely quantified using highly sensitive digital PCR assays to analyze amplifications of EGFR, MET, FGFR3, MYC, ERBB2, and MYCN genes at +3, +6, and +12 copies against a single well-characterized genomic background (GM24385).

"The lack of realistic reference materials representing a broad range of cancer somatic aberrations has been a challenge for test developers and clinical labs alike when it comes to measuring accuracy of NGS tumor profiling tests " said Anna V. Hartwig, PhD, VP of R&D, TOMA Biosciences. "SeraCare reference materials have already enabled us to benchmark the ability of our assay to identify SNVs, indels, and rearrangements. Now with the new Seraseq CNV reference materials for detecting and quantifying oncogenic amplifications typical of breast, lung, and brain cancers, we have a complete tool set for the analytical validation of labs using our assay. This tool set is a great asset in advancing the ultimate end-goal of driving accurate diagnosis and management of treatment options available to cancer patients."

"With the release of the industry's first quantitative CNV-focused reference materials for tumor profiling, we continue our commitment and leadership in the clinical genomics market.  SeraCare now offers the industry's widest portfolio of clinical genomics QC reference materials and software for applications that include tumor profiling, liquid biopsy, heme malignancies, inherited disease testing, and NIPT. Our innovative products developed with ground-breaking technology and partnerships with key industry experts are now significantly accelerating new assay development and validation, along with providing confidence in the accuracy of routine assay results, in a wide range of laboratories worldwide." said Trevor Brown, VP for the Clinical Genomics Business Unit at SeraCare.

SeraCare will be on-hand in Booth #406 at the 2018 Tri-Con Meeting in San Francisco, CA, from February 12-16 to discuss the new Seraseq Breast CNV and Seraseq Lung & Brain CNV reference materials, their complete QC solution, and the VariantFlex platform for rapid, easy, custom reference materials that fit almost any lab's budget. There will also be an industry-sponsored symposium on ctDNA reference materials in the development and validation of liquid biopsy NGS assays, to be presented by Dr. Brian Haynes, Associate Director of Bioinformatics, Asuragen, Inc., on February 15 at 10:00 am.

Learn more about the Seraseq CNV reference materials at https://www.seracare.com/cnvs.

About SeraCare Life Sciences, Inc.

SeraCare enables the promise of precision medicine by advancing the understanding of disease and providing assurance of the diagnostic result. Our innovative tools and technologies not only provide assurance of the safe, effective, and accurate performance of diagnostic assays but also establish a framework for regulating, compiling, and interpreting data from precision diagnostics. Our portfolio includes a broad range of products such as quality control technologies, disease-state specimens and tissues for research and development, processed biological materials, and immunoassay reagents. For more information, please visit www.seracare.com and follow SeraCare on Twitter (@SeraCare).

Company Contact:
Heather DelCarpini
SeraCare Life Sciences, Inc.
508.244.6429
hdelcarpini@seracare.com
www.seracare.com

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/seracare-announces-industrys-first-cnv-specific-reference-material-for-gene-amplifications-in-breast-lung-and-brain-cancer-300597951.html

SOURCE SeraCare Life Sciences

Copyright 2018 PR Newswire

Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V:us D:20180815 02:54:29